Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
Absorptiometry, Photon
Aged
Anastrozole
/ administration & dosage
Aromatase Inhibitors
/ administration & dosage
Bone Density
/ drug effects
Breast Neoplasms
/ prevention & control
Case-Control Studies
Double-Blind Method
Female
Femur Neck
/ diagnostic imaging
Humans
Middle Aged
Postmenopause
Spine
/ diagnostic imaging
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
17
06
2020
accepted:
10
12
2020
revised:
01
12
2020
pubmed:
27
1
2021
medline:
23
9
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. One thousand four hundred and ten women were included in a BMD substudy and stratified into three strata according to their baseline T-score at spine or femoral neck. The primary objective of this analysis was to investigate whether DXA BMD at the spine and hip changed two years after treatment cessation (between years 5 and 7) in those who did not receive risedronate. Five- and seven-year BMD data were available for a total of 528 women who did not receive risedronate. In women with normal BMD at baseline, an increase in BMD at the lumbar spine after anastrozole withdrawal was observed 1.25% (95% CI 0.73 to 1.77) (P = 0.0004), which was larger than in those on placebo (0.14% (-0.29 to 0.56))). At the hip, BMD remained unchanged between years 5 and 7 for those previously on anastrozole but continued to a decrease in those who had been randomised to placebo (-1.35% (-1.70 to -0.98)). These are the first results reporting BMD changes after stopping anastrozole in a breast cancer prevention setting. Our results show that the negative effects of anastrozole on BMD in the preventive setting are partially reversible.
Sections du résumé
BACKGROUND
Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment.
METHODS
One thousand four hundred and ten women were included in a BMD substudy and stratified into three strata according to their baseline T-score at spine or femoral neck. The primary objective of this analysis was to investigate whether DXA BMD at the spine and hip changed two years after treatment cessation (between years 5 and 7) in those who did not receive risedronate.
RESULTS
Five- and seven-year BMD data were available for a total of 528 women who did not receive risedronate. In women with normal BMD at baseline, an increase in BMD at the lumbar spine after anastrozole withdrawal was observed 1.25% (95% CI 0.73 to 1.77) (P = 0.0004), which was larger than in those on placebo (0.14% (-0.29 to 0.56))). At the hip, BMD remained unchanged between years 5 and 7 for those previously on anastrozole but continued to a decrease in those who had been randomised to placebo (-1.35% (-1.70 to -0.98)).
CONCLUSIONS
These are the first results reporting BMD changes after stopping anastrozole in a breast cancer prevention setting. Our results show that the negative effects of anastrozole on BMD in the preventive setting are partially reversible.
Identifiants
pubmed: 33495601
doi: 10.1038/s41416-020-01228-2
pii: 10.1038/s41416-020-01228-2
pmc: PMC8039042
doi:
Substances chimiques
Aromatase Inhibitors
0
Anastrozole
2Z07MYW1AZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1373-1378Subventions
Organisme : Cancer Research UK
ID : 5032
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Références
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135–1141 (2010).
doi: 10.1016/S1470-2045(10)70257-6
Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E. et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369, 559–570 (2007).
doi: 10.1016/S0140-6736(07)60200-1
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793–1802 (2003).
doi: 10.1056/NEJMoa032312
Goss, P. E., Ingle, J. N., Ales-Martinez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381–2391 (2011).
doi: 10.1056/NEJMoa1103507
Cheung, A. M., Tile, L., Cardew, S., Pruthi, S., Robbins, J., Tomlinson, G. et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 13, 275–284 (2012).
doi: 10.1016/S1470-2045(11)70389-8
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383, 1041–1048 (2014).
doi: 10.1016/S0140-6736(13)62292-8
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Cawthorn, S., Mansel, R. E. et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395, 117–122 (2020).
doi: 10.1016/S0140-6736(19)32955-1
Sestak, I., Singh, S., Cuzick, J., Blake, G. M., Patel, R., Gossiel, F. et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 15, 1460–1468 (2014).
doi: 10.1016/S1470-2045(14)71035-6
Sestak, I., Blake, G. M., Patel, R., Coleman, R. E., Cuzick, J. & Eastell, R. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone 124, 83–88 (2019).
doi: 10.1016/j.bone.2019.04.016
GE Medical systems. DPX Series Operator’s Manual. GE Healthcare, 1998.
Kelly, T. L. Bone mineral density reference databases for American men and women. J. Bone Mine. Res. 5((Suppl 1), S249 (1990).
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P. et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos. Int. 8, 468–489 (1998).
doi: 10.1007/s001980050093
Khosla, S., Melton, L. J. 3rd & Riggs, B. L. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J. Bone Min. Res. 26, 441–451 (2011).
doi: 10.1002/jbmr.262
Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J. et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 8, 119–127 (2007).
doi: 10.1016/S1470-2045(07)70003-7
Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J. et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J. Clin. Oncol. 26, 1051–1057 (2008).
doi: 10.1200/JCO.2007.11.0726
Hadji, P., Asmar, L., van Nes, J. G., Menschik, T., Hasenburg, A., Kuck, J. et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J. Cancer Res. Clin. Oncol. 137, 1015–1025 (2011).
doi: 10.1007/s00432-010-0964-y
Eastell, R., Adams, J., Clack, G., Howell, A., Cuzick, J., Mackey, J. et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann. Oncol. 22, 857–862 (2011).
doi: 10.1093/annonc/mdq541
Coleman, R. E., Banks, L. M., Girgis, S. I., Vrdoljak, E., Fox, J., Cawthorn, S. J. et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res. Treat. 124, 153–161 (2010).
doi: 10.1007/s10549-010-1121-7
Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290, 1729–1738 (2003).
doi: 10.1001/jama.290.13.1729
Watts, N. B., Chines, A., Olszynski, W. P., McKeever, C. D., McClung, M. R., Zhou, X. et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19, 365–372 (2008).
doi: 10.1007/s00198-007-0460-7
Gossiel, F., Altaher, H., Reid, D. M., Roux, C., Felsenberg, D., Gluer, C. C. et al. Bone turnover markers after the menopause: T-score approach. Bone 111, 44–48 (2018).
doi: 10.1016/j.bone.2018.03.016